Loss-of-function mutations in SLC30A8 protect against type 2 diabetes.

Loss-of-function mutations protective against human disease provide in vivo validation of therapeutic targets, but none have yet been described for type 2 diabetes (T2D). Through sequencing or genotyping of ~150,000 individuals across 5 ancestry groups, we identified 12 rare protein-truncating varia...

Celý popis

Podrobná bibliografie
Hlavní autoři:	Flannick, J, Thorleifsson, G, Beer, N, Jacobs, S, Grarup, N, Burtt, N, Mahajan, A, Fuchsberger, C, Atzmon, G, Benediktsson, R, Blangero, J, Bowden, D, Brandslund, I, Brosnan, J, Burslem, F, Chambers, J, Cho, Y, Christensen, C, Douglas, D, Duggirala, R, Dymek, Z, Farjoun, Y, Fennell, T, Fontanillas, P, Forsén, T
Médium:	Journal article
Jazyk:	English
Vydáno:	2014

Loss-of-function mutations in SLC30A8 protect against type 2 diabetes Autor Flannick, J, Thorleifsson, G, Beer, N, Jacobs, S, Grarup, N, Burtt, N, Mahajan, A, Fuchsberger, C, Atzmon, G, Benediktsson, R, Blangero, J, Bowden, D, Brandslund, I, Brosnan, J, Burslem, F, Chambers, J, Cho, Y, Christensen, C, Douglas, D, Duggirala, R, Dymek, Z, Farjoun, Y, Fennell, T, Fontanillas, P, Forsén, T

Vydáno 2014

Journal article

Loss-of-function mutations in SLC30A8 protect against type 2 diabetes.

Podobné jednotky